---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-101434"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-09-18T20:27:15+00:00"
generated_at: "2026-09-18T20:28:14.691214+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Adial shareholders approve 5x authorized-share increase to 500M and new 2026 equity plans

## Summary
- Authorized common shares increased from 100M to 500M (1,239,968 votes for, 37,210 against).
- 2026 Equity Incentive Plan approved: 3,078,147 new shares plus 196,670 returning shares and 5% annual evergreen through Jan 1, 2036.
- Series F warrant exercise issuance of up to 552,940 shares approved under Nasdaq Listing Rule 5635(d).
- 2017 Plan share pool raised from 200,000 to 225,666 shares; ESPP approved; CBIZ CPAs ratified as auditor.
- Meeting partially adjourned on 4 proposals pending Nasdaq conditional approval; reconvenes Oct 1, 2026.

## SEC filing metadata
- accession: 0001213900-26-101434
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-09-18T20:27:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026101434/0001213900-26-101434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026101434/ea0305933-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-101434
- JSON: https://secwatch.observer/filing/0001213900-26-101434.json
- Plain text: https://secwatch.observer/filing/0001213900-26-101434.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.